Analyst Price Target is $36.50
▲ +9.35% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $36.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 9.35% upside from the last price of $33.38.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in TransMedics Group. This rating has held steady since February 2021, when it changed from a Hold consensus rating.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.